Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.

[1]  Simon A. Jones,et al.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[3]  B. Piraino,et al.  Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[4]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[5]  S. Rose-John,et al.  Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. , 2000, Circulation.

[6]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[7]  Simon A. Jones,et al.  Brief Definitive Report C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding , 1999 .

[8]  M. Manns,et al.  The Designer Cytokine Hyper-Interleukin-6 Is a Potent Activator of STAT3-dependent Gene Transcription in Vivoand in Vitro * , 1999, The Journal of Biological Chemistry.

[9]  P. Heinrich,et al.  Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. , 1998, Journal of immunology.

[10]  Koyanagi,et al.  High‐level production of alternatively spliced soluble interleukin‐6 receptor in serum of patients with adult T‐cell leukaemia/HTLV‐I‐associated myelopathy , 1998, Immunology.

[11]  Simon A. Jones,et al.  Shedding of the soluble IL‐6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP‐1 cells , 1998, European journal of immunology.

[12]  S. Rose-John,et al.  In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. , 1998, Journal of immunology.

[13]  J. Burke,et al.  Disruption of the Cellular Inflammatory Response to Listeria monocytogenes Infection in Mice with Disruptions in Targeted Genes , 1998, Infection and Immunity.

[14]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[15]  M. Jordana,et al.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.

[16]  G. Zimmerman,et al.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. , 1997, The Journal of clinical investigation.

[17]  T. Vischer,et al.  Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.

[18]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[19]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[20]  S. Rose-John,et al.  The function of the soluble IL-6 receptor in vivo. , 1996, Immunology letters.

[21]  A. Davenport,et al.  Activation of inflammation and leukocyte recruitment into the peritoneal cavity. , 1996, Kidney international. Supplement.

[22]  G. Coles,et al.  Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. , 1996, Kidney international.

[23]  C. Haslett,et al.  In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. , 1996, Journal of immunology.

[24]  D. Payan,et al.  Neutrophil rolling altered by inhibition of L-selectin shedding in vitro , 1996, Nature.

[25]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[26]  B. Hylander,et al.  Tumor necrosis factor-α, interleukin-1β, and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis , 1996 .

[27]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.

[28]  J. Grötzinger,et al.  The Soluble Interleukin‐6 Receptor a , 1995, Annals of the New York Academy of Sciences.

[29]  M. Waki,et al.  Soluble interleukin‐6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism , 1994, European journal of immunology.

[30]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[31]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.

[32]  J. Westwick,et al.  Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. , 1993, The American journal of pathology.

[33]  B. Barton,et al.  Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model , 1993, Infection and immunity.

[34]  P. Heinrich,et al.  The soluble interleukin‐6 receptor is generated by shedding , 1993, European journal of immunology.

[35]  R. Kyle,et al.  Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. , 1992, Cytokine.

[36]  D. Remick,et al.  Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. , 1991, The American journal of pathology.

[37]  G. Coles,et al.  Eicosanoid synthesis in human peritoneal macrophages stimulated with S. epidermidis. , 1990, Kidney international.

[38]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.